Literature DB >> 34636022

Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study.

Piero Ruscitti1, Ilenia Di Cola2, Onorina Berardicurti2, Alessandro Conforti2, Daniela Iacono3, Ilenia Pantano3, Gelsomina Rozza3, Silvia Rossi4, Ludovico De Stefano4, Silvia Balduzzi4, Antonio Vitale5, Francesco Caso6, Luisa Costa6, Marcella Prete7, Luca Navarini8, Fabiola Atzeni9, Giuliana Guggino10, Federico Perosa7, Luca Cantarini5, Bruno Frediani5, Carlomaurizio Montecucco4, Francesco Ciccia3, Roberto Giacomelli8, Paola Cipriani2.   

Abstract

The objective of this study is to describe the possible prognostic impact of smoking habit on adult-onset Still's disease (AOSD) patients, by the assessment of clinical characteristics, life-threatening complications occurrence, and mortality in smokers than non-smokers. A multicentre retrospective study of prospectively followed-up AOSD patients included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort was conducted. Out of 185 AOSD assessed patients, 45 smokers were identified. These showed a higher frequency of pericarditis (35.5% vs 16.4%, p = 0.011), pleuritis (33.3% vs 14.3%, p = 0.008), and abdominal pain (17.7% vs 6.4%, p = 0.035). Furthermore, smokers showed higher values of systemic score (6.4 ± 2.2 vs 5.4 ± 1.8, p = 0.004), an increased rate of macrophage activation syndrome (MAS) (28.9% vs 6.4%, p < 0.0001) and of parenchymal lung disease (17.7% vs 12.6%, p = 0.035). Although not significant, these patients more frequently experienced a poor prognosis (13.3% vs 4.3%, p = 0.074). Smoking habit predicted MAS occurrence in both univariate (HR: 5.98, 95% CI: 2.45-14.57, p < 0.0001) and multivariate regression models (HR: 6.21, 95% CI: 2.46-15.70, p < 0.0001). Smokers had a significant higher risk of parenchymal lung disease in both univariate (HR: 3.97, 95% CI: 1.43-11.02, p = 0.008) and multivariate regression models (HR: 3.90, 95% CI: 1.36-11.23, p = 0.012). Smoking habit also increased the risk of mortality in univariate regression model (HR: 4.25, 95% CI: 1.33-13.55, p = 0.015). Smoking habit resulted to be a negative prognostic factor on AOSD patients. Smokers were characterised by a higher frequency of serositis and higher values of systemic score. Additionally, these patients were more frequently burdened by MAS and parenchymal lung disease associated with a poor prognosis. Key points • Smoking habit resulted to be a negative prognostic factor on AOSD. • Smokers were characterised by an increased frequency of serositis and higher values of systemic score. • Cigarette exposure was associated with MAS and parenchymal lung disease in AOSD.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Adult-onset; Macrophage activation syndrome; Mortality; Smoking; Still’s disease

Mesh:

Year:  2021        PMID: 34636022     DOI: 10.1007/s10067-021-05929-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  23 in total

Review 1.  The impact of lifestyle behaviours, physical activity and smoking on morbidity and mortality in patients with rheumatoid arthritis.

Authors:  James M Gwinnutt; Suzanne Mm Verstappen; Jenny H Humphreys
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-07-06       Impact factor: 4.098

2.  Association of Smoking and Obesity on the Risk of Developing Primary Sjögren Syndrome: A Population-based Cohort Study.

Authors:  Luisa Servioli; Gabriel Maciel; Carlotta Nannini; Cynthia S Crowson; Eric L Matteson; Divi Cornec; Alvise Berti
Journal:  J Rheumatol       Date:  2019-01-15       Impact factor: 4.666

Review 3.  A comprehensive review on adult onset Still's disease.

Authors:  Roberto Giacomelli; Piero Ruscitti; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2018-08-01       Impact factor: 7.094

4.  Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.

Authors:  Grant S Schulert; Shima Yasin; Brenna Carey; Claudia Chalk; Thuy Do; Andrew H Schapiro; Ammar Husami; Allen Watts; Hermine I Brunner; Jennifer Huggins; Elizabeth D Mellins; Esi M Morgan; Tracy Ting; Bruce C Trapnell; Kathryn A Wikenheiser-Brokamp; Christopher Towe; Alexei A Grom
Journal:  Arthritis Rheumatol       Date:  2019-10-01       Impact factor: 10.995

5.  Association Between Cigarette Smoking and Systemic Lupus Erythematosus: An Updated Multivariate Bayesian Metaanalysis.

Authors:  Monica Hui Yan Chua; Irene Ai Ting Ng; Mike W L-Cheung; Anselm Mak
Journal:  J Rheumatol       Date:  2019-12-01       Impact factor: 4.666

Review 6.  Pathogenesis of adult onset still's disease: current understanding and new insights.

Authors:  Piero Ruscitti; Roberto Giacomelli
Journal:  Expert Rev Clin Immunol       Date:  2018-10-12       Impact factor: 4.473

7.  Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis.

Authors:  Amélie Seguin; Lionel Galicier; David Boutboul; Virginie Lemiale; Elie Azoulay
Journal:  Chest       Date:  2016-01-13       Impact factor: 9.410

8.  Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients.

Authors:  Piero Ruscitti; Onorina Berardicurti; Daniela Iacono; Ilenia Pantano; Vasiliki Liakouli; Francesco Caso; Giacomo Emmi; Rosa Daniela Grembiale; Francesco Paolo Cantatore; Fabiola Atzeni; Federico Perosa; Raffaele Scarpa; Giuliana Guggino; Francesco Ciccia; Antonio Barile; Paola Cipriani; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2020-06-22       Impact factor: 5.156

Review 9.  Mechanisms, biomarkers and targets for adult-onset Still's disease.

Authors:  Eugen Feist; Stéphane Mitrovic; Bruno Fautrel
Journal:  Nat Rev Rheumatol       Date:  2018-10       Impact factor: 20.543

Review 10.  Life-threatening complications of adult-onset Still's disease.

Authors:  Petros Efthimiou; Sabeeda Kadavath; Bella Mehta
Journal:  Clin Rheumatol       Date:  2014-01-17       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.